Sign inJoin waitlistJoin the waitlist

Jeffrey Taub

Chief of Oncology · Children's Hospital of Michigan

Credentials: · · · ·

History

Oncology Division · Children's Hospital of Michigan
Present
Children's Hospital of Michigan
Present
Children's Hospital of Michigan
Present

Pediatric Hematology Oncology
Children's Hospital of Michigan
1991–1994
Pediatrics
Children's Hospital of Michigan
1988–1991
Western University
1987–1988
UNIV OF WESTERN ONTARIO, FAC OF MED, LONDON, ONTARIO, CANADA
1983–1987

Research

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
The Lancet Oncology · 2010 · 467 citations
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
Clinical Cancer Research · 2016 · 214 citations
A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481
Blood · 2006 · 199 citations

YR
Yaddanapudi Ravindranath
34 papers
Hiroto Inaba
13 papers
JR
Jeffrey Rubnitz
13 papers
Ching-Hon Pui
12 papers
Timothy Caldwell
11 papers · 2 as a fellow
Tristan Knight
11 papers · 6 as a fellow
Ana Xavier
10 papers · 3 as a fellow
Raul Ribeiro
10 papers
Alan Gamis
9 papers
Dario Campana
9 papers
Gary Dahl
9 papers
JY
Jay Yang
8 papers

Grants

Enhancing Treatments for Myeloid Leukemia Associated with Down Syndrome
National Cancer Institute · R01
Contact PI · $931.8K · Wayne State University
2024–2028
The Paradox of Myeloid Leukemia of Down Syndrome
National Cancer Institute · R21
Contact PI · $396K · Wayne State University
2023–2026
Molecular and Pharmacologic Correletes of Acute Myeloid Leukemia in Down Syndrome
National Cancer Institute · R01
Contact PI · $2.1M · Wayne State University
2007–2014
Cystathionine B Synthase and ARA C Therapy for Leukemia
National Cancer Institute · R01
Contact PI · $1.2M · Wayne State University
2001–2007

Clinical trials

Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial
Principal investigator · Completed
Children's Oncology Group
2012
Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder
Principal investigator · Completed
Children's Oncology Group
2012–2016
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
Principal investigator · Completed · Phase 3
Children's Oncology Group
2007–2021
Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder
Study chair · Withdrawn · Phase 3
Children's Oncology Group
2006–2007